USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
AGENNIX, INC.
Address:
AGENNIX, INC.
8 GREENWAY PLZ, STE 910
HOUSTON, TX 77046 0892
Phone:
N/A
URL:
N/A
EIN:
954405779
DUNS:
808956700
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
Yes

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,908,936.00 7
SBIR Phase II $4,498,960.00 4
STTR Phase I $221,691.00 3
STTR Phase II $274,703.00 1

Award List:

THERAPY FOR GASTROINTESTINAL DISORDERS

Award Year / Program / Phase:
1999 / STTR / Phase I
Award Amount:
$105,891.00
Agency:
HHS
Principal Investigator:
Dial
Research Institution:
University of Texas
RI Contact:
N/A
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$100,733.00
Agency:
HHS
Principal Investigator:
Pauline Ward
Abstract:
N/a

Therapy for gastrointestinal disorders

Award Year / Program / Phase:
2001 / STTR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER
RI Contact:
N/A
Abstract:
DESCRIPTION (Applicant's Abstract): The overall goal of this research proposal is to determine the effectiveness of recombinant human lactoferrin (rhLF) for treating gastrointestinal (GI) disorders. This Phase II proposal will focus on the ability of rhLF to treat the 01 side… More

Safety and efficacy of rh-Lactoferrin in Diabetic Ulcers

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$100,035.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Research Objectives: Determine the safety, pharmacokinetics, pharmacodynamics, and efficacy of topical recombinant human lactoferrin (rhLF) in promoting healing in diabetic ulcers. There are 7.5 million US patients with chronic skin wounds with annual… More

Safety and efficacy of rh-Lactoferrin in Diabetic Ulcers

Award Year / Program / Phase:
2004 / SBIR / Phase II
Award Amount:
$715,265.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Research Objectives: Determine the safety, pharmacokinetics, pharmacodynamics, and efficacy of topical recombinant human lactoferrin (rhLF) in promoting healing in diabetic ulcers. There are 7.5 million US patients with chronic skin wounds with annual… More

Recombinant human lactoferrin to treat oral mucositis

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$349,929.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION: Oral mucositis is a major dose-limiting toxic effect of intensive cancer chemotherapy and radiotherapy. In addition to the morbidity directly caused by severe oral mucositis, it can cause secondary morbidities by limiting oral intake or even lead to dose reduction or delay in further… More

Lactoferrin in Primate and Mouse Models of Asthma

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$99,925.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The purpose of this research is to extend work to determine the efficacy of orally administered recombinant human lactoferrin (rhLF) in an established primate model of asthma. Asthma is one of the most prevalent chronic inflammatory diseases in the United States… More

Recombinant Lactoferrin and Necrotizing Enterocolitis

Award Year / Program / Phase:
2004 / STTR / Phase I
Award Amount:
$115,800.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF CALIFORNIA DAVIS
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): This feasibility study is based on our hypothesis that recombinant human lactoferrin [rhLF] can prevent or reduce severity of necrotizing enterocolitis [NEC]. NEC is mainly a disease of very low birth weight [VLBW] human infants. It is a leading cause of… More

Phase II Clinical Trial of Lactoferrin in Asthma

Award Year / Program / Phase:
2005 / SBIR / Phase II
Award Amount:
$749,920.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The purpose of this research is to determine the efficacy of orally administered recombinant human lactoferrin (rhLF) in Phase II clinical trials in patients with mild to moderate asthma. Asthma is one of the most prevalent chronic inflammatory diseases in the… More

Treatment of Sepsis using Recombinant Human Lactoferrin

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$130,595.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Severe sepsis is a major cause of mortality and morbidity in the US (Angus DC et al., 2001) with some 751,000 cases annually, costing on average over $22,000/case, and resulting in 215,000 deaths (28.6% mortality rate). The incidence of sepsis cases has been… More

Treatment of Sepsis with Talactoferrin

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$570,399.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Severe sepsis is a major cause of morbidity and mortality throughout the world. It is the leading cause of death in non-coronary intensive care units (ICUs) in the United States, with more than 750,000 cases occurring e very year. This means that in the United… More

Lactoferrin Enhances Growth and Reduces Nosocomial Infection in Preterm Infants

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$557,320.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This project aims to develop talactoferrin (TLF, recombinant human lactoferrin) as a therapeutic agent to treat prematurely born neonates. The treatment will be given orally shortly after birth to prevent nosocomial inf ections (NIs) due to abnormal bacterial… More

Treatment of Sepsis with Talactoferrin

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$2,462,044.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Severe sepsis is a major cause of morbidity and mortality throughout the world. It is the leading cause of death in non-coronary intensive care units (ICUs) in the United States, with more than 750,000 cases occurring e very year. This means that in the United… More

Lactoferrin Enhances Growth and Reduces Nosocomial Infection in Preterm Infants

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$571,731.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This project aims to develop talactoferrin (TLF, recombinant human lactoferrin) as a therapeutic agent to treat prematurely born neonates. The treatment will be given orally shortly after birth to prevent nosocomial inf ections (NIs) due to abnormal bacterial… More